Ipamorelin 10 mg (≥99% Purity) — Research Use Only

Elevate your studies with Ipamorelin, a selective ghrelin receptor (GHS-R1a) agonist supplied by Peptide Tech at ≥99% purity (HPLC/MS verified). This RUO pentapeptide is ideal for in-vitro, cellular, and biochemical investigations of GHS-R signaling, pituitary GH release models, and receptor-selectivity profiling. Not for human or veterinary use.

Specifications

Chemical Name	Ipamorelin (NNC 26-0161)
Sequence	H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂
CAS Number	170851-70-4
PubChem CID	CID 9831659
Molecular Formula	C₃₈H₄₉N₉O₅
Molecular Weight (avg.)	≈ 711.85 g/mol
Monoisotopic Mass	≈ 711.39 Da
Physical Appearance	White to off-white lyophilized powder
Container	3 mL Type I glass vial (10 mg net content)
Purity	≥ 99% (verified by HPLC & MS; 3rd-party tested)
Solubility	Soluble in sterile water or compatible buffer; for difficult matrices, pre-wet with ≤0.1% acetic acid or minimal DMSO, then bring to final buffer. 0.22 µm filter-sterilize if required.

Molecular Structure

Ipamorelin 2D structure (PubChem CID 9831659) — View on PubChem (CID 9831659)

Why Peptide Tech

Same-Day Shipping
GMP-Aligned Lyophilized Peptides
USA Made
24/7 Support
Price Match Guarantee
Batch Tracking with QR Code Verification
3rd-Party USA Lab Testing — purity, quantity, endotoxin
Cold-Chain Shipping — Always (no paid upgrade)
Worldwide Shipping
All Major Payments Accepted
Text & Email Order Updates
2-Day FedEx/UPS Shipping Standard
Cheapest Overnight Rates
Largest Variety of Peptides & Bioregulators

Storage & Handling

Lyophilized (unopened): Store at ≤ −20 °C, desiccated and protected from light. For long-term archival, ≤ −80 °C is recommended.
After reconstitution: Aliquot into sterile, low-binding tubes; store at ≤ −80 °C. Avoid repeated freeze–thaw cycles.
Handling: Allow vial to reach room temperature before opening to minimize condensation. Use sterile technique and neutral pH buffers; add carrier protein (e.g., 0.1% BSA) if adsorption is a concern.
Research Use Only (RUO): Not for human or veterinary use, ingestion, diagnostic, or therapeutic applications.

Potential Applications in Research

Strictly in-vitro, cellular, or biochemical contexts — no clinical or human-use claims.

GHS-R1a receptor pharmacology & selectivity: Compare Ipamorelin’s selective GH secretagogue activity vs. other GHRPs in pituitary cell assays.
Raun et al., 1998.
Pituitary GH release models: Quantify dose-response (EC₅₀, E_max) for GH secretion in primary pituitary cultures.
Raun et al., 1998.
PK/PD method development: Use controlled infusion/exposure data to build compartmental models and exposure–response relationships for secretagogue activity.
Gobburu et al., 1999.
GI motility pathways (preclinical): Explore ghrelin-receptor–mediated effects on gastric contractility and transit in rodent surgical models (mechanistic endpoints only).
Greenwood-Van Meerveld et al., 2012.

Citations (PubMed)

Raun, K., et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998;139(5):552–561.
PMID: 9849822
Gobburu, J.V.S., Agersø, H., Jusko, W.J., Ynddal, L. “Pharmacokinetic–pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.” Pharmaceutical Research, 1999;16(9):1412–1416.
PMID: 10496658
Greenwood-Van Meerveld, B., Tyler, K., Mohammadi, E., Pietra, C. “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.” Journal of Experimental Pharmacology, 2012;4:149–155.
PMID: 27186127

Compliance & RUO Disclaimer

For laboratory research use only (RUO). Not a drug, food, or cosmetic. Not for human or veterinary use. Purchase and use are limited to qualified personnel operating under institutional laboratory guidelines.

Ipamorelin 10mg